UBS Group
ARTV

UBS Group’s Artiva Biotherapeutics ARTV Stock Holding History

UBS Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.83K Sell
1,527
-35,346
-96% -$175K ﹤0.01% 8411
2025
Q4 		$158K Buy
36,873
+15,730
+74% +$59.4K ﹤0.01% 6690
2025
Q3 		$60.7K Buy
21,143
+17,806
+534% +$47.6K ﹤0.01% 7429
2025
Q2 		$5.04K Sell
3,337
-39,740
-92% -$83.5K ﹤0.01% 9215
2025
Q1 		$129K Buy
43,077
+7,698
+22% +$41.6K ﹤0.01% 6845
2024
Q4 		$357K Buy
35,379
+28,761
+435% +$345K ﹤0.01% 6078
2024
Q3 		$102K Buy
+6,618
New +$76.7K ﹤0.01% 6344

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

UBS Group's ARTV Position: Q1 2026 in Review

UBS Group reduced its Artiva Biotherapeutics (ARTV) stake by 96% in Q1 2026, selling an estimated $175K and leaving 1,527 shares worth $9.83K. The position accounts for ﹤0.01% of the portfolio, ranked #8411.

UBS Group first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $357K in Q4 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • UBS Group held 1,527 shares of Artiva Biotherapeutics worth $9.83K as of Q1 2026.
  • UBS Group sold 35,346 Artiva Biotherapeutics shares in Q1 2026, an estimated $175K.
  • Artiva Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8411 holding.
  • UBS Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • UBS Group's Artiva Biotherapeutics position peaked at $357K in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.